Nanoskalige Glykopeptid-Konjugate als Melanom-assoziierte vollsynthetische Vakzine für die Antitumor-Immuntherapie (B13)

• Fachliche Zuordnung: Immunologie
• Förderung: Förderung seit 2017
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 213555243

TP B13 established a modular vaccine platform using molecular (glyco)peptide building blocks. These carry tumor-associated antigens or immuno-stimulatory components and co-assemble into anisotropic multifunc-tional nanorods. The platform was successfully applied as fully synthetic vaccines against tumor-associated Mucin 1 during the previous funding period and will now be used to develop vaccines against malignant melanoma. Synthetic B-cell epitopes derived from melanoma associated surface protein CSPG4 will be co-presented on the nanorod surface, with T-cell epitopes and immunomodulating agents, and will be evaluated in vivo in terms of tumor-specific antibody induction and therapeutic effect.

• DFG-Verfahren: Sonderforschungsbereiche
• Teilprojekt zu: SFB 1066: Nanodimensionale polymere Therapeutika für die Tumortherapie
• Antragstellende Institution: Johannes Gutenberg-Universität Mainz
• Teilprojektleiter: Professor Dr. Pol Besenius; Professor Dr. Tobias Bopp; Professor Dr. Edgar Schmitt, bis 6/2021